G?s is critical for the actions of PTH and PTHrP. The gene encoding G?s (GNAS) also gives rise to XL?s, which is expressed in various tissues including osteoblastic and renal cells. XL?s can mimic G?s by stimulating cAMP generation in response PTH, although it is also predicted to have unique actions. Mutations in GNAS are found in several human diseases that impair signaling through the PTH/PTHrP receptor (PTHR). Most of these mutations affect both G?s and XL?s. Studies in mice and humans indicate that XL?s plays important roles in physiology and human disease, but the actions of XL?s remain poorly understood. Our recent studies have provided novel insights into the cellular actions of XL?s, and together with our findings obtained from XL?s knockout (XLKO) mice, these led us to hypothesize that XL?s is necessary for the regulation of calcium and phosphorus metabolism in vivo.
In Aim 1 of the current proposal, we will address whether XL?s is necessary for PTH-mediated actions in the renal proximal tubule during early postnatal development. We will determine a) whether proximal tubular actions of PTH in XLKO mice are impaired and b) whether the PTH resistance phenotype in XLKO mice is rescued by transgenically reconstituting XL?s expression in the proximal tubule.
In Aim 2, we will address whether XL?s allows PTH actions to be sustained in the renal proximal tubule, which could explain the PTH resistance phenotype in XLKO mice. We will thus determine a) whether PTHR internalization is enhanced in the proximal tubule of XLKO mice;b) whether the PTH resistance phenotype in XLKO mice can be rescued by a mutant PTHR with sustained activity or by overexpressing G?s in the proximal tubule;and c) whether the interaction of XL?s with dynamin influences PTH actions. These studies will provide novel insights into the actions of PTH and XL?s in the renal proximal tubule, and these will be applicable to the actions of these proteins in skeletal tissues. Our results will also help reveal the roles of XL?s in other systems, in addition to improving our knowledge of the mechanisms underlying the diseases caused by GNAS mutations. Given that XL?s can activate the ubiquitous cAMP signaling pathway, our results will likely have even broader implications for human health and disease.
|Wentworth, Kelly; Hsing, Alyssa; Urrutia, Ashley et al. (2016) A Novel T55A Variant of Gs Î± Associated with Impaired cAMP Production, Bone Fragility, and Osteolysis. Case Rep Endocrinol 2016:2691385|
|Zhu, Yan; He, Qing; Aydin, Cumhur et al. (2016) Ablation of the Stimulatory G Protein Î±-Subunit in Renal Proximal Tubules Leads to Parathyroid Hormone-Resistance With Increased Renal Cyp24a1 mRNA Abundance and Reduced Serum 1,25-Dihydroxyvitamin D. Endocrinology 157:497-507|
|Turan, Serap; Bastepe, Murat (2015) GNAS Spectrum of Disorders. Curr Osteoporos Rep 13:146-58|
|Turan, Serap; Thiele, Susanne; Tafaj, Olta et al. (2015) Evidence of hormone resistance in a pseudo-pseudohypoparathyroidism patient with a novel paternal mutation in GNAS. Bone 71:53-7|
|He, Qing; Zhu, Yan; Corbin, Braden A et al. (2015) The G protein Î± subunit variant XLÎ±s promotes inositol 1,4,5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo. Sci Signal 8:ra84|
|Turan, Serap; Fernandez-Rebollo, Eduardo; Aydin, Cumhur et al. (2014) Postnatal establishment of allelic GÎ±s silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous GÎ±s disruption. J Bone Miner Res 29:749-60|
|Turan, Serap; Bastepe, Murat (2013) The GNAS complex locus and human diseases associated with loss-of-function mutations or epimutations within this imprinted gene. Horm Res Paediatr 80:229-41|
|Erickson, Catherine E; Gul, Rukhsana; Blessing, Christopher P et al. (2013) The Î²-blocker Nebivolol Is a GRK/Î²-arrestin biased agonist. PLoS One 8:e71980|
|Mahon, M J (2012) The parathyroid hormone receptorsome and the potential for therapeutic intervention. Curr Drug Targets 13:116-28|
|Turan, Serap; Ignatius, Jaakko; Moilanen, Jukka S et al. (2012) De novo STX16 deletions: an infrequent cause of pseudohypoparathyroidism type Ib that should be excluded in sporadic cases. J Clin Endocrinol Metab 97:E2314-9|
Showing the most recent 10 out of 31 publications